EMEA (Europe, Middle East and Africa) ENG(Endoglin precursor) Market Report 2017

January 2018 | 125 pages | ID: E6C7FBC0669EN
QYResearch

Abstracts

In this report, the EMEA ENG(Endoglin precursor) market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (MT), revenue (Million USD), market share and growth rate of ENG(Endoglin precursor) for these regions, from 2012 to 2022 (forecast)

• Europe: Germany, France, UK, Russia, Italy and Benelux;
• Middle East: Saudi Arabia, Israel, UAE and Iran;
• Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA ENG(Endoglin precursor) market competition by top manufacturers/players, with ENG(Endoglin precursor) sales volume (MT), price (USD/Kg), revenue (Million USD) and market share for each manufacturer/player; the top players including

• Aviva Systems Biology Corporation(USA)
• Atlas Antibodies(Sweden)
• Abbexa Ltd(UK)
• Abiocode(US)
• Boster Biological Technology(USA)
• Biobyt(UK)
• Bio-Rad(US)
• Bioss Antibodies(US)
• Biosensis(US)
• BioLegend(US)
• BioVision(US)
• BethylLaboratories(US)
• Epigentek(US)
• EnzoLifeSciences(Switzerland)
• Genetex(US)
• Lifespan Biosciences(US)
• Novus Biologicals(US)
• Proteintech(US)
• ProSci(US)
• ProteoGenix(France)
• R&D Systems(US)
• Rockland(US)
• St John's Laboratory Ltd(UK)
• Stemcell(Canada)
• Thermo Fisher Scientific(US)
• USBiological(US)

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into

• Above 90%
• Above 95%
• Above 99%
• Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

• Biopharmaceutical Companies
• Hospitals
• Bioscience Research Institutions
• Others

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

EMEA (Europe, Middle East and Africa) ENG(Endoglin precursor) Market Report 2017

1 ENG(ENDOGLIN PRECURSOR) OVERVIEW

1.1 Product Overview and Scope of ENG(Endoglin precursor)
1.2 Classification of ENG(Endoglin precursor)
  1.2.1 EMEA ENG(Endoglin precursor) Market Size (Sales) Comparison by Type (2012-2022)
  1.2.2 EMEA ENG(Endoglin precursor) Market Size (Sales) Market Share by Type (Product Category) in 2016
  1.2.3 Above 90%
  1.2.4 Above 95%
  1.2.5 Above 99%
  1.2.6 Others
1.3 EMEA ENG(Endoglin precursor) Market by Application/End Users
  1.3.1 EMEA ENG(Endoglin precursor) Sales (Volume) and Market Share Comparison by Application (2012-2022
  1.3.2 Biopharmaceutical Companies
  1.3.3 Hospitals
  1.3.4 Bioscience Research Institutions
  1.3.5 Others
1.4 EMEA ENG(Endoglin precursor) Market by Region
  1.4.1 EMEA ENG(Endoglin precursor) Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 Europe Status and Prospect (2012-2022)
  1.4.3 Middle East Status and Prospect (2012-2022)
  1.4.4 Africa Status and Prospect (2012-2022)
1.5 EMEA Market Size (Value and Volume) of ENG(Endoglin precursor) (2012-2022)
  1.5.1 EMEA ENG(Endoglin precursor) Sales and Growth Rate (2012-2022)
  1.5.2 EMEA ENG(Endoglin precursor) Revenue and Growth Rate (2012-2022)

2 EMEA ENG(ENDOGLIN PRECURSOR) COMPETITION BY MANUFACTURERS/PLAYERS/SUPPLIERS, REGION, TYPE AND APPLICATION

2.1 EMEA ENG(Endoglin precursor) Market Competition by Players/Manufacturers
  2.1.1 EMEA ENG(Endoglin precursor) Sales Volume and Market Share of Major Players (2012-2017)
  2.1.2 EMEA ENG(Endoglin precursor) Revenue and Share by Players (2012-2017)
  2.1.3 EMEA ENG(Endoglin precursor) Sale Price by Players (2012-2017)
2.2 EMEA ENG(Endoglin precursor) (Volume and Value) by Type/Product Category
  2.2.1 EMEA ENG(Endoglin precursor) Sales and Market Share by Type (2012-2017)
  2.2.2 EMEA ENG(Endoglin precursor) Revenue and Market Share by Type (2012-2017)
  2.2.3 EMEA ENG(Endoglin precursor) Sale Price by Type (2012-2017)
2.3 EMEA ENG(Endoglin precursor) (Volume) by Application
2.4 EMEA ENG(Endoglin precursor) (Volume and Value) by Region
  2.4.1 EMEA ENG(Endoglin precursor) Sales and Market Share by Region (2012-2017)
  2.4.2 EMEA ENG(Endoglin precursor) Revenue and Market Share by Region (2012-2017)
  2.4.3 EMEA ENG(Endoglin precursor) Sales Price by Region (2012-2017)

3 EUROPE ENG(ENDOGLIN PRECURSOR) (VOLUME, VALUE AND SALES PRICE), BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

3.1 Europe ENG(Endoglin precursor) Sales and Value (2012-2017)
  3.1.1 Europe ENG(Endoglin precursor) Sales Volume and Growth Rate (2012-2017)
  3.1.2 Europe ENG(Endoglin precursor) Revenue and Growth Rate (2012-2017)
3.2 Europe ENG(Endoglin precursor) Sales and Market Share by Type
3.3 Europe ENG(Endoglin precursor) Sales and Market Share by Application
3.4 Europe ENG(Endoglin precursor) Sales Volume and Value (Revenue) by Countries
  3.4.1 Europe ENG(Endoglin precursor) Sales Volume by Countries (2012-2017)
  3.4.2 Europe ENG(Endoglin precursor) Revenue by Countries (2012-2017)
  3.4.3 Germany ENG(Endoglin precursor) Sales and Growth Rate (2012-2017)
  3.4.4 France ENG(Endoglin precursor) Sales and Growth Rate (2012-2017)
  3.4.5 UK ENG(Endoglin precursor) Sales and Growth Rate (2012-2017)
  3.4.6 Russia ENG(Endoglin precursor) Sales and Growth Rate (2012-2017)
  3.4.7 Italy ENG(Endoglin precursor) Sales and Growth Rate (2012-2017)
  3.4.8 Benelux ENG(Endoglin precursor) Sales and Growth Rate (2012-2017)

4 MIDDLE EAST ENG(ENDOGLIN PRECURSOR) (VOLUME, VALUE AND SALES PRICE), BY REGION, TYPE AND APPLICATION

4.1 Middle East ENG(Endoglin precursor) Sales and Value (2012-2017)
  4.1.1 Middle East ENG(Endoglin precursor) Sales Volume and Growth Rate (2012-2017)
  4.1.2 Middle East ENG(Endoglin precursor) Revenue and Growth Rate (2012-2017)
4.2 Middle East ENG(Endoglin precursor) Sales and Market Share by Type
4.3 Middle East ENG(Endoglin precursor) Sales and Market Share by Application
4.4 Middle East ENG(Endoglin precursor) Sales Volume and Value (Revenue) by Countries
  4.4.1 Middle East ENG(Endoglin precursor) Sales Volume by Countries (2012-2017)
  4.4.2 Middle East ENG(Endoglin precursor) Revenue by Countries (2012-2017)
  4.4.3 Saudi Arabia ENG(Endoglin precursor) Sales and Growth Rate (2012-2017)
  4.4.4 Israel ENG(Endoglin precursor) Sales and Growth Rate (2012-2017)
  4.4.5 UAE ENG(Endoglin precursor) Sales and Growth Rate (2012-2017)
  4.4.6 Iran ENG(Endoglin precursor) Sales and Growth Rate (2012-2017)

5 AFRICA ENG(ENDOGLIN PRECURSOR) (VOLUME, VALUE AND SALES PRICE) BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

5.1 Africa ENG(Endoglin precursor) Sales and Value (2012-2017)
  5.1.1 Africa ENG(Endoglin precursor) Sales Volume and Growth Rate (2012-2017)
  5.1.2 Africa ENG(Endoglin precursor) Revenue and Growth Rate (2012-2017)
5.2 Africa ENG(Endoglin precursor) Sales and Market Share by Type
5.3 Africa ENG(Endoglin precursor) Sales and Market Share by Application
5.4 Africa ENG(Endoglin precursor) Sales Volume and Value (Revenue) by Countries
  5.4.1 Africa ENG(Endoglin precursor) Sales Volume by Countries (2012-2017)
  5.4.2 Africa ENG(Endoglin precursor) Revenue by Countries (2012-2017)
  5.4.3 South Africa ENG(Endoglin precursor) Sales and Growth Rate (2012-2017)
  5.4.4 Nigeria ENG(Endoglin precursor) Sales and Growth Rate (2012-2017)
  5.4.5 Egypt ENG(Endoglin precursor) Sales and Growth Rate (2012-2017)
  5.4.6 Algeria ENG(Endoglin precursor) Sales and Growth Rate (2012-2017)

6 EMEA ENG(ENDOGLIN PRECURSOR) MANUFACTURERS/PLAYERS PROFILES AND SALES DATA

6.1 Aviva Systems Biology Corporation(USA)
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 ENG(Endoglin precursor) Product Type, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Aviva Systems Biology Corporation(USA) ENG(Endoglin precursor) Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Atlas Antibodies(Sweden)
  6.2.1 Company Basic Information, Manufacturing Base and Competitors
  6.2.2 ENG(Endoglin precursor) Product Type, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Atlas Antibodies(Sweden) ENG(Endoglin precursor) Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Abbexa Ltd(UK)
  6.3.1 Company Basic Information, Manufacturing Base and Competitors
  6.3.2 ENG(Endoglin precursor) Product Type, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Abbexa Ltd(UK) ENG(Endoglin precursor) Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 Abiocode(US)
  6.4.1 Company Basic Information, Manufacturing Base and Competitors
  6.4.2 ENG(Endoglin precursor) Product Type, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Abiocode(US) ENG(Endoglin precursor) Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Boster Biological Technology(USA)
  6.5.1 Company Basic Information, Manufacturing Base and Competitors
  6.5.2 ENG(Endoglin precursor) Product Type, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Boster Biological Technology(USA) ENG(Endoglin precursor) Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 Biobyt(UK)
  6.6.1 Company Basic Information, Manufacturing Base and Competitors
  6.6.2 ENG(Endoglin precursor) Product Type, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Biobyt(UK) ENG(Endoglin precursor) Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 Bio-Rad(US)
  6.7.1 Company Basic Information, Manufacturing Base and Competitors
  6.7.2 ENG(Endoglin precursor) Product Type, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Bio-Rad(US) ENG(Endoglin precursor) Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview
6.8 Bioss Antibodies(US)
  6.8.1 Company Basic Information, Manufacturing Base and Competitors
  6.8.2 ENG(Endoglin precursor) Product Type, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 Bioss Antibodies(US) ENG(Endoglin precursor) Sales, Revenue, Price and Gross Margin (2012-2017)
  6.8.4 Main Business/Business Overview
6.9 Biosensis(US)
  6.9.1 Company Basic Information, Manufacturing Base and Competitors
  6.9.2 ENG(Endoglin precursor) Product Type, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 Biosensis(US) ENG(Endoglin precursor) Sales, Revenue, Price and Gross Margin (2012-2017)
  6.9.4 Main Business/Business Overview
6.10 BioLegend(US)
  6.10.1 Company Basic Information, Manufacturing Base and Competitors
  6.10.2 ENG(Endoglin precursor) Product Type, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 BioLegend(US) ENG(Endoglin precursor) Sales, Revenue, Price and Gross Margin (2012-2017)
  6.10.4 Main Business/Business Overview
6.11 BioVision(US)
6.12 BethylLaboratories(US)
6.13 Epigentek(US)
6.14 EnzoLifeSciences(Switzerland)
6.15 Genetex(US)
6.16 Lifespan Biosciences(US)
6.17 Novus Biologicals(US)
6.18 Proteintech(US)
6.19 ProSci(US)
6.20 ProteoGenix(France)
6.21 R&D Systems(US)
6.22 Rockland(US)
6.23 St John's Laboratory Ltd(UK)
6.24 Stemcell(Canada)
6.25 Thermo Fisher Scientific(US)
6.26 USBiological(US)

7 ENG(ENDOGLIN PRECURSOR) MANUFACTURING COST ANALYSIS

7.1 ENG(Endoglin precursor) Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of ENG(Endoglin precursor)

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 ENG(Endoglin precursor) Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of ENG(Endoglin precursor) Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 EMEA ENG(ENDOGLIN PRECURSOR) MARKET FORECAST (2017-2022)

11.1 EMEA ENG(Endoglin precursor) Sales, Revenue and Price Forecast (2017-2022)
  11.1.1 EMEA ENG(Endoglin precursor) Sales and Growth Rate Forecast (2017-2022)
  11.1.2 EMEA ENG(Endoglin precursor) Revenue and Growth Rate Forecast (2017-2022)
  11.1.3 EMEA ENG(Endoglin precursor) Price and Trend Forecast (2017-2022)
11.2 EMEA ENG(Endoglin precursor) Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.3 Europe ENG(Endoglin precursor) Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.4 Middle Eastt ENG(Endoglin precursor) Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.5 Africa ENG(Endoglin precursor) Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.6 EMEA ENG(Endoglin precursor) Sales Forecast by Type (2017-2022)
11.7 EMEA ENG(Endoglin precursor) Sales Forecast by Application (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of ENG(Endoglin precursor)
Figure EMEA ENG(Endoglin precursor) Sales Volume (MT) by Type (2012-2022)
Figure EMEA ENG(Endoglin precursor) Sales Volume Market Share by Type (Product Category) in 2016
Figure Above 90% Product Picture
Figure Above 95% Product Picture
Figure Above 99% Product Picture
Figure Others Product Picture
Figure EMEA ENG(Endoglin precursor) Sales Volume (MT) by Application (2012-2022)
Figure EMEA Sales Market Share of ENG(Endoglin precursor) by Application in 2016
Figure Biopharmaceutical Companies Examples
Table Key Downstream Customer in Biopharmaceutical Companies
Figure Hospitals Examples
Table Key Downstream Customer in Hospitals
Figure Bioscience Research Institutions Examples
Table Key Downstream Customer in Bioscience Research Institutions
Figure Others Examples
Table Key Downstream Customer in Others
Figure EMEA ENG(Endoglin precursor) Market Size (Million USD) by Region (2012-2022)
Figure Europe ENG(Endoglin precursor) Revenue (Million USD) and Growth Rate (2012-2022)
Figure Europe ENG(Endoglin precursor) Revenue (Million USD) Status and Forecast by Countries
Figure Middle East ENG(Endoglin precursor) Revenue (Million USD) and Growth Rate (2012-2022)
Figure Middle East ENG(Endoglin precursor) Revenue (Million USD) Status and Forecast by Countries
Figure Africa ENG(Endoglin precursor) Revenue (Million USD) and Growth Rate (2012-2022)
Figure Africa ENG(Endoglin precursor) Revenue (Million USD) Status and Forecast by Countries
Figure EMEA ENG(Endoglin precursor) Sales Volume and Growth Rate (2012-2022)
Figure EMEA ENG(Endoglin precursor) Revenue (Million USD) and Growth Rate (2012-2022)
Figure EMEA ENG(Endoglin precursor) Market Major Players Product Sales Volume (MT) (2012-2017)
Table EMEA ENG(Endoglin precursor) Sales Volume (MT) of Major Players (2012-2017)
Table EMEA ENG(Endoglin precursor) Sales Share by Players (2012-2017)
Figure 2016 ENG(Endoglin precursor) Sales Share by Players
Figure 2017 ENG(Endoglin precursor) Sales Share by Players
Figure EMEA ENG(Endoglin precursor) Market Major Players Product Revenue (Million USD) (2012-2017)
Table EMEA ENG(Endoglin precursor) Revenue (Million USD) by Players (2012-2017)
Table EMEA ENG(Endoglin precursor) Revenue Share by Players (2012-2017)
Table 2016 EMEA ENG(Endoglin precursor) Revenue Share by Players
Table 2017 EMEA ENG(Endoglin precursor) Revenue Share by Players
Table EMEA ENG(Endoglin precursor) Sale Price (USD/Kg) by Players (2012-2017)
Table EMEA ENG(Endoglin precursor) Sales (MT) and Market Share by Type (2012-2017)
Table EMEA ENG(Endoglin precursor) Sales Share by Type (2012-2017)
Figure Sales Market Share of ENG(Endoglin precursor) by Type (2012-2017)
Figure EMEA ENG(Endoglin precursor) Sales Market Share by Type (2012-2017)
Table EMEA ENG(Endoglin precursor) Revenue (Million USD) and Market Share by Type (2012-2017)
Table EMEA ENG(Endoglin precursor) Revenue Share by Type (2012-2017)
Figure Revenue Market Share of ENG(Endoglin precursor) by Type in 2016
Table EMEA ENG(Endoglin precursor) Sale Price (USD/Kg) by Type (2012-2017)
Table EMEA ENG(Endoglin precursor) Sales (MT) and Market Share by Application (2012-2017)
Table EMEA ENG(Endoglin precursor) Sales Share by Application (2012-2017)
Figure Sales Market Share of ENG(Endoglin precursor) by Application (2012-2017)
Figure EMEA ENG(Endoglin precursor) Sales Market Share by Application in 2016
Table EMEA ENG(Endoglin precursor) Sales (MT) and Market Share by Region (2012-2017)
Table EMEA ENG(Endoglin precursor) Sales Share by Region (2012-2017)
Figure Sales Market Share of ENG(Endoglin precursor) by Region (2012-2017)
Figure EMEA ENG(Endoglin precursor) Sales Market Share in 2016
Table EMEA ENG(Endoglin precursor) Revenue (Million USD) and Market Share by Region (2012-2017)
Table EMEA ENG(Endoglin precursor) Revenue Share by Region (2012-2017)
Figure Revenue Market Share of ENG(Endoglin precursor) by Region (2012-2017)
Figure EMEA ENG(Endoglin precursor) Revenue Market Share Regions in 2016
Table EMEA ENG(Endoglin precursor) Sales Price (USD/Kg) by Region (2012-2017)
Figure Europe ENG(Endoglin precursor) Sales (MT) and Growth Rate (2012-2017)
Figure Europe ENG(Endoglin precursor) Revenue and Growth Rate (2012-2017)
Table Europe ENG(Endoglin precursor) Sales (MT) by Type (2012-2017)
Table Europe ENG(Endoglin precursor) Market Share by Type (2012-2017)
Figure Europe ENG(Endoglin precursor) Market Share by Type in 2016
Table Europe ENG(Endoglin precursor) Sales (MT) by Application (2012-2017)
Table Europe ENG(Endoglin precursor) Market Share by Application (2012-2017)
Figure Europe ENG(Endoglin precursor) Market Share by Application in 2016
Table Europe ENG(Endoglin precursor) Sales (MT) by Countries (2012-2017)
Table Europe ENG(Endoglin precursor) Sales Market Share by Countries (2012-2017)
Figure Europe ENG(Endoglin precursor) Sales Market Share by Countries (2012-2017)
Figure Europe ENG(Endoglin precursor) Sales Market Share by Countries in 2016
Table Europe ENG(Endoglin precursor) Revenue (Million USD) by Countries (2012-2017)
Table Europe ENG(Endoglin precursor) Revenue Market Share by Countries (2012-2017)
Figure Europe ENG(Endoglin precursor) Revenue Market Share by Countries (2012-2017)
Figure Europe ENG(Endoglin precursor) Revenue Market Share by Countries in 2016
Figure Germany ENG(Endoglin precursor) Sales (MT) and Growth Rate (2012-2017)
Figure France ENG(Endoglin precursor) Sales (MT) and Growth Rate (2012-2017)
Figure UK ENG(Endoglin precursor) Sales (MT) and Growth Rate (2012-2017)
Figure Russia ENG(Endoglin precursor) Sales (MT) and Growth Rate (2012-2017)
Figure Italy ENG(Endoglin precursor) Sales (MT) and Growth Rate (2012-2017)
Figure Benelux ENG(Endoglin precursor) Sales (MT) and Growth Rate (2012-2017)
Figure Middle East ENG(Endoglin precursor) Sales (MT) and Growth Rate (2012-2017)
Figure Middle East ENG(Endoglin precursor) Revenue (Million USD) and Growth Rate (2012-2017)
Table Middle East ENG(Endoglin precursor) Sales (MT) by Type (2012-2017)
Table Middle East ENG(Endoglin precursor) Market Share by Type (2012-2017)
Figure Middle East ENG(Endoglin precursor) Market Share by Type (2012-2017)
Table Middle East ENG(Endoglin precursor) Sales (MT) by Applications (2012-2017)
Table Middle East ENG(Endoglin precursor) Market Share by Applications (2012-2017)
Figure Middle East ENG(Endoglin precursor) Sales Market Share by Application in 2016
Table Middle East ENG(Endoglin precursor) Sales Volume (MT) by Countries (2012-2017)
Table Middle East ENG(Endoglin precursor) Sales Volume Market Share by Countries (2012-2017)
Figure Middle East ENG(Endoglin precursor) Sales Volume Market Share by Countries in 2016
Table Middle East ENG(Endoglin precursor) Revenue (Million USD) by Countries (2012-2017)
Table Middle East ENG(Endoglin precursor) Revenue Market Share by Countries (2012-2017)
Figure Middle East ENG(Endoglin precursor) Revenue Market Share by Countries (2012-2017)
Figure Middle East ENG(Endoglin precursor) Revenue Market Share by Countries in 2016
Figure Saudi Arabia ENG(Endoglin precursor) Sales (MT) and Growth Rate (2012-2017)
Figure Israel ENG(Endoglin precursor) Sales (MT) and Growth Rate (2012-2017)
Figure UAE ENG(Endoglin precursor) Sales (MT) and Growth Rate (2012-2017)
Figure Iran ENG(Endoglin precursor) Sales (MT) and Growth Rate (2012-2017)
Figure Africa ENG(Endoglin precursor) Sales (MT) and Growth Rate (2012-2017)
Figure Africa ENG(Endoglin precursor) Revenue (Million USD) and Growth Rate (2012-2017)
Table Africa ENG(Endoglin precursor) Sales (MT) by Type (2012-2017)
Table Africa ENG(Endoglin precursor) Sales Market Share by Type (2012-2017)
Figure Africa ENG(Endoglin precursor) Sales Market Share by Type (2012-2017)
Figure Africa ENG(Endoglin precursor) Sales Market Share by Type in 2016
Table Africa ENG(Endoglin precursor) Sales (MT) by Application (2012-2017)
Table Africa ENG(Endoglin precursor) Sales Market Share by Application (2012-2017)
Figure Africa ENG(Endoglin precursor) Sales Market Share by Application (2012-2017)
Table Africa ENG(Endoglin precursor) Sales Volume (MT) by Countries (2012-2017)
Table Africa ENG(Endoglin precursor) Sales Market Share by Countries (2012-2017)
Figure Africa ENG(Endoglin precursor) Sales Market Share by Countries (2012-2017)
Figure Africa ENG(Endoglin precursor) Sales Market Share by Countries in 2016
Table Africa ENG(Endoglin precursor) Revenue (Million USD) by Countries (2012-2017)
Table Africa ENG(Endoglin precursor) Revenue Market Share by Countries (2012-2017)
Figure Africa ENG(Endoglin precursor) Revenue Market Share by Countries (2012-2017)
Figure Africa ENG(Endoglin precursor) Revenue Market Share by Countries in 2016
Figure South Africa ENG(Endoglin precursor) Sales (MT) and Growth Rate (2012-2017)
Figure Nigeria ENG(Endoglin precursor) Sales (MT) and Growth Rate (2012-2017)
Figure Egypt ENG(Endoglin precursor) Sales (MT) and Growth Rate (2012-2017)
Figure Algeria ENG(Endoglin precursor) Sales (MT) and Growth Rate (2012-2017)
Table Aviva Systems Biology Corporation(USA) ENG(Endoglin precursor) Basic Information List
Table Aviva Systems Biology Corporation(USA) ENG(Endoglin precursor) Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Aviva Systems Biology Corporation(USA) ENG(Endoglin precursor) Sales (MT) and Growth Rate (2012-2017)
Figure Aviva Systems Biology Corporation(USA) ENG(Endoglin precursor) Sales Market Share in EMEA (2012-2017)
Figure Aviva Systems Biology Corporation(USA) ENG(Endoglin precursor) Revenue Market Share in EMEA (2012-2017)
Table Atlas Antibodies(Sweden) ENG(Endoglin precursor) Basic Information List
Table Atlas Antibodies(Sweden) ENG(Endoglin precursor) Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Atlas Antibodies(Sweden) ENG(Endoglin precursor) Sales (MT) and Growth Rate (2012-2017)
Figure Atlas Antibodies(Sweden) ENG(Endoglin precursor) Sales Market Share in EMEA (2012-2017)
Figure Atlas Antibodies(Sweden) ENG(Endoglin precursor) Revenue Market Share in EMEA (2012-2017)
Table Abbexa Ltd(UK) ENG(Endoglin precursor) Basic Information List
Table Abbexa Ltd(UK) ENG(Endoglin precursor) Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Abbexa Ltd(UK) ENG(Endoglin precursor) Sales (MT) and Growth Rate (2012-2017)
Figure Abbexa Ltd(UK) ENG(Endoglin precursor) Sales Market Share in EMEA (2012-2017)
Figure Abbexa Ltd(UK) ENG(Endoglin precursor) Revenue Market Share in EMEA (2012-2017)
Table Abiocode(US) ENG(Endoglin precursor) Basic Information List
Table Abiocode(US) ENG(Endoglin precursor) Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Abiocode(US) ENG(Endoglin precursor) Sales (MT) and Growth Rate (2012-2017)
Figure Abiocode(US) ENG(Endoglin precursor) Sales Market Share in EMEA (2012-2017)
Figure Abiocode(US) ENG(Endoglin precursor) Revenue Market Share in EMEA (2012-2017)
Table Boster Biological Technology(USA) ENG(Endoglin precursor) Basic Information List
Table Boster Biological Technology(USA) ENG(Endoglin precursor) Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Boster Biological Technology(USA) ENG(Endoglin precursor) Sales (MT) and Growth Rate (2012-2017)
Figure Boster Biological Technology(USA) ENG(Endoglin precursor) Sales Market Share in EMEA (2012-2017)
Figure Boster Biological Technology(USA) ENG(Endoglin precursor) Revenue Market Share in EMEA (2012-2017)
Table Biobyt(UK) ENG(Endoglin precursor) Basic Information List
Table Biobyt(UK) ENG(Endoglin precursor) Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Biobyt(UK) ENG(Endoglin precursor) Sales (MT) and Growth Rate (2012-2017)
Figure Biobyt(UK) ENG(Endoglin precursor) Sales Market Share in EMEA (2012-2017)
Figure Biobyt(UK) ENG(Endoglin precursor) Revenue Market Share in EMEA (2012-2017)
Table Bio-Rad(US) ENG(Endoglin precursor) Basic Information List
Table Bio-Rad(US) ENG(Endoglin precursor) Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Bio-Rad(US) ENG(Endoglin precursor) Sales (MT) and Growth Rate (2012-2017)
Figure Bio-Rad(US) ENG(Endoglin precursor) Sales Market Share in EMEA (2012-2017)
Figure Bio-Rad(US) ENG(Endoglin precursor) Revenue Market Share in EMEA (2012-2017)
Table Bioss Antibodies(US) ENG(Endoglin precursor) Basic Information List
Table Bioss Antibodies(US) ENG(Endoglin precursor) Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Bioss Antibodies(US) ENG(Endoglin precursor) Sales (MT) and Growth Rate (2012-2017)
Figure Bioss Antibodies(US) ENG(Endoglin precursor) Sales Market Share in EMEA (2012-2017)
Figure Bioss Antibodies(US) ENG(Endoglin precursor) Revenue Market Share in EMEA (2012-2017)
Table Biosensis(US) ENG(Endoglin precursor) Basic Information List
Table Biosensis(US) ENG(Endoglin precursor) Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Biosensis(US) ENG(Endoglin precursor) Sales (MT) and Growth Rate (2012-2017)
Figure Biosensis(US) ENG(Endoglin precursor) Sales Market Share in EMEA (2012-2017)
Figure Biosensis(US) ENG(Endoglin precursor) Revenue Market Share in EMEA (2012-2017)
Table BioLegend(US) ENG(Endoglin precursor) Basic Information List
Table BioLegend(US) ENG(Endoglin precursor) Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure BioLegend(US) ENG(Endoglin precursor) Sales (MT) and Growth Rate (2012-2017)
Figure BioLegend(US) ENG(Endoglin precursor) Sales Market Share in EMEA (2012-2017)
Figure BioLegend(US) ENG(Endoglin precursor) Revenue Market Share in EMEA (2012-2017)
Table BioVision(US) ENG(Endoglin precursor) Basic Information List
Table BethylLaboratories(US) ENG(Endoglin precursor) Basic Information List
Table Epigentek(US) ENG(Endoglin precursor) Basic Information List
Table EnzoLifeSciences(Switzerland) ENG(Endoglin precursor) Basic Information List
Table Genetex(US) ENG(Endoglin precursor) Basic Information List
Table Lifespan Biosciences(US) ENG(Endoglin precursor) Basic Information List
Table Novus Biologicals(US) ENG(Endoglin precursor) Basic Information List
Table Proteintech(US) ENG(Endoglin precursor) Basic Information List
Table ProSci(US) ENG(Endoglin precursor) Basic Information List
Table ProteoGenix(France) ENG(Endoglin precursor) Basic Information List
Table R&D Systems(US) ENG(Endoglin precursor) Basic Information List
Table Rockland(US) ENG(Endoglin precursor) Basic Information List
Table St John's Laboratory Ltd(UK) ENG(Endoglin precursor) Basic Information List
Table Stemcell(Canada) ENG(Endoglin precursor) Basic Information List
Table Thermo Fisher Scientific(US) ENG(Endoglin precursor) Basic Information List
Table USBiological(US) ENG(Endoglin precursor) Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of ENG(Endoglin precursor)
Figure Manufacturing Process Analysis of ENG(Endoglin precursor)
Figure ENG(Endoglin precursor) Industrial Chain Analysis
Table Raw Materials Sources of ENG(Endoglin precursor) Major Manufacturers in 2016
Table Major Buyers of ENG(Endoglin precursor)
Table Distributors/Traders List
Figure EMEA ENG(Endoglin precursor) Sales (MT) and Growth Rate Forecast (2017-2022)
Figure EMEA ENG(Endoglin precursor) Revenue and Growth Rate Forecast (2017-2022)
Figure EMEA ENG(Endoglin precursor) Price (USD/Kg) and Trend Forecast (2017-2022)
Table EMEA ENG(Endoglin precursor) Sales (MT) Forecast by Region (2017-2022)
Figure EMEA ENG(Endoglin precursor) Sales Market Share Forecast by Region (2017-2022)
Table EMEA ENG(Endoglin precursor) Revenue (Million USD) Forecast by Region (2017-2022)
Figure EMEA ENG(Endoglin precursor) Revenue Market Share Forecast by Region (2017-2022)
Table Europe ENG(Endoglin precursor) Sales (MT) Forecast by Countries (2017-2022)
Figure Europe ENG(Endoglin precursor) Sales Market Share Forecast by Countries (2017-2022)
Table Europe ENG(Endoglin precursor) Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Europe ENG(Endoglin precursor) Revenue Market Share Forecast by Countries (2017-2022)
Table Middle East ENG(Endoglin precursor) Sales (MT) Forecast by Countries (2017-2022)
Figure Middle East ENG(Endoglin precursor) Sales Market Share Forecast by Countries (2017-2022)
Table Middle East ENG(Endoglin precursor) Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Middle East ENG(Endoglin precursor) Revenue Market Share Forecast by Countries (2017-2022)
Table Africa ENG(Endoglin precursor) Sales (MT) Forecast by Countries (2017-2022)
Figure Africa ENG(Endoglin precursor) Sales Market Share Forecast by Countries (2017-2022)
Table Africa ENG(Endoglin precursor) Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Africa ENG(Endoglin precursor) Revenue Market Share Forecast by Countries (2017-2022)
Table EMEA ENG(Endoglin precursor) Sales (MT) Forecast by Type (2017-2022)
Figure EMEA ENG(Endoglin precursor) Sales Market Share Forecast by Type (2017-2022)
Table EMEA ENG(Endoglin precursor) Sales (MT) Forecast by Application (2017-2022)
Figure EMEA ENG(Endoglin precursor) Sales Market Share Forecast by Application (2017-2022)
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources